Buradasınız

Anasayfa » Content

VİRAL ETİYOLOJİLİ KRONİK KARACİĞER HASTALARINDA KARACİĞER FİBROZİSİ İÇİN BİYOKİMYASAL GÖSTERGELER

Journal Name:

  • İstanbul Tıp Fakültesi Dergisi

Publication Year:

  • 2004

Key Words:

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
Biochemical markers of Uver fibrosis in patients witlı ehronic viral /iver disease. Liver biopsy is the gold standard for the diagnosis of ehronic viral liver disease. Bccause liver biopsy is an invasive procedure, development of noninvasİve biochemical markers reflecting liver fibrosis is a necessity. The aim of our study is to determine the diagnostjc accuracy of serum hyaluronat and procoHagen III N-terminal peptide (PIIINP) levels for the evahıation of liver fibrosis in ehronic viral liver disease. 183 ehronic hepatitis patients with viral etiology were ineluded in our study (112 male, mean 44.4+13.7 year) and liver biopsy and/or laparoseopy were done in eacb. When the valucs of "the area under the receiver operating characterİstic (AUROC)" were calculated, (hey were found to be 0.892 + 0.027 for hyaluronat and 0.658 + 0.048 for PIIINP İn seperence cirrhosİs. The dİagnostic accuracy of serum hyaluronate and PIIINP for severe fibrosis (F3-F4) were 76% (cut-off value, 60 ng/ml) and 53.7% (cut-off value, 6.4 pg/1) and for cirrhosis werc 75.2% (cut-off value, 60 ng/ml) and 60,5% (cut-off value, 6.4 pg/1) res-pectivcly, Accordİng to our resuttSj it should bc considered that serum hyaluronat levels nıay be uscd as a noninvasive marker for diagnosis of chirrosis or severe fibrosis in viral liver disease.
Bookmark/Search this post with
Abstract (Original Language): 
Karaciğer biyopsisi, kronik karaciğer hastalığının tanısında altın standarttır. Ancak biyopsinin invaziv bir işlem olması, karaciğer fibrozisini yansıtan noninvaziv biyokimyasal göstergelerin geliştirilmesini zorunlu kılmaktadır. Çalışmamızın amacı, vira! etiyolojili kronik karaciğer hastalığında serum hyaluronat vc prokoliajen III N-terminal peptid (PII1NP) düzeylerinin karaciğer fibrozisini göstermedeki tanısal doğruluğunu saptamaktır. Çalışmaya viral etiyolojili 183 kronik hepatitÜ hasta afındı (112 erkek, ortalama yaş 44.4+13.7 yıl) ve hepsine karaciğer ponksiyon biyopsisi ve/veya laparoskopi yapıldı. ROC eğrileri ile hesaplandığında "the area under the receiver operating characterİstic (AUROC)" değerleri, sirozu göstermede hyaluronat için 0.892 ± 0.027, PIIINP için 0.658 ± 0.048 olarak bulundu. İleri fibrozisi (F3-F4) saptamada tanısal doğruluk oranları hyaluronat için (eşik değer 60 ng/ml) %76, PIIINP için (eşik değer 6.4 ug/1) %53.7, sirozu saptamada tanısal doğruluk oranları hyaluronat için (eşik değer 100 ng/ml) %75.2, PIIINP için (eşik değer 6.4 ug/i) %60.5 saptandı. Sonuçlarımız serum hyaluronat düzeylerinin viral etiyolojili karaciğer sirozunun veya ileri fibrozisinin tanısında noninvaziv bir gösterge olarak kullanılabileceği düşündürmektedir.
FULL TEXT (PDF): 
PDF icon arastirmax-viral-etiyolojili-kronik-karaciger-hastalarinda-karaciger-fibrozisi-icin-biyokimyasal-gostergeler.pdf
  • 4
229-235
  • Turkish

REFERENCES

References: 

1. Perrillo RP; The role of liver biopsy in hepatilis C. Hepatology; 1997; 26:57.
2. EASL Inlernatİonal Consensus Conference on Hepatilis C: Paris, February 26-27, 1999. Consensus statcnıent. J Hepatol; 1999; 31: 3.
3. Cadranel JF, Rufat P, Degos F: Practices of liver biopsy in Fraııce:resui!s of a prospective nationwide survey. For the Group of Epidemİology of tlıe French Associatioıı for the Study of the Liver (AFEF). Hepatology; 2000; 32: 477.
4. Froehlich F, Lamy O, Fried M, Gonvcrs JJ: Practice and conıplicalions of liver biopsy. Resulls of a ııationvvide survey in Switzerland. Dig Dis Sci; 1993; 38: 1480.
5. McGill DB, Rakela J, Zinsmeistcr AR, Ott BJ: A 21 -year experience with raajor hemorrhage afler percutaneous liver biopsy. Gastroenterology; 1990; 99: 1396.
6. Oberti F, Valsesia E, Pİleltc C et al: Noninvazive diagnosis of hepalic fibrosis or cirrhosis. Gastroenterology; 1997;Î13; 1609.
7. Tran A, Hastier P, Barjoan EM et al: Non invasive pre-diclion of severe fibrosis in patients with alcoholic liver disease. Gastroenterol Clin Biol.; 2000; 24: 626.
ü. Leroy V, Traversay C, Barnoud R ct al: Changes in his-tological lesions and serum fibrogene.sis markers in ehronic hepatitis C patients tıoıı-rcsponders to interferoıı- ?. J Hepatol.; 2001; 35:120.
9. Ishtbashi K, Kaslıiwagi T, Ito A el al: Changes İn serum fibrogenesis markers during inteıferon therapy for ehronic heaptilis type C. Hepatology; 1996; 1:27.
10. Murawaki Y, Ikula Y, Okamolo K et al: Diagııostic value of serum markers of conneclive tissue tumover lor pre-dicling hislological slaging and grading in patients wilh ehronic hepatilis C. J Gastroenteroi; 2001; 6: 399.
11. Myers RP, Ratziu V, Imbeıt-Bismul F, Charlotte F, Poy-nard T: Biochemical markers of liver fivrosis: A compa-rison wilh lıistortcal icatures İn patients vvitb ehronic hc-patitis C. The MULTIVIRC group. Ara J Gastroenterol; 2002; 97: 2419.
12. Myers RP, De Torres M, Imberl-Bismut F, Ratziu V, Charlotte F, Poynaıd T: Biochemical markers of fibrosis in patients with ehronic hepatitis C. The MULTIVIRC group. Dig Dis Sci; 42003; 8: 146.
13. Lu LG, Zeng M D, Wan MB, Li CZ, Mao YM, Li JQ, Oiu DK, Cao AP, Ye J, Cai X, Chen CW, VVaııg JY, Wu SM, Zhu JS, Zhou XQ; Grading and stagtng of hepalic fibrosis, and its reiationship witb noninvasive diagnostic paramelers. World J Gastroenterol; 2003; 9: 2574.
14. Ramadori G, Zoehrens G, Manns MP, Rider H, Dicnes HP, Hess G, Meyer-z. Buescbenfelde KH: Serum hyalıı-ronate and type III procollagen aminoterminal propeptide concentralion in ehronic liver disease. Reiationship to
cirrhosis and disease aetivity. Eur J Clin Invest 1991; 21:323.
15. Sotaniemi EA, Mungan Z, Ristelli J et al: Serum type III procollagen and basement membrane antigens in hepatitis B virüs liver disease. Euro J İnternal Mcd.; 1992; 3:131.
16. Tcare JP, Sherman D, Greenfield SM et al: Comparison of serum procollagen III peptide concentrations and PGA index for assessment of hepatic fibrosis. Lancel; 1993; 342:895.
17. Jeröme G, Rence EP, Philİppe G et al: Reiationship bet-ween procollagen III aminoterminal propeptide and hya-luronan serum levels and histological fibrosis in primary biliary cirrhosis and ehronic vira! hepatitis C. J Hepatol.; 1994;20:388.
18. Takato U, Sadalaka I, Michİo S et al: Serum hyaluronate predicts response to interferon-? therapy in patients wilh ehronic hepatilis C. Hepato-Gaslroentcrology; 1995; 42:522.
19. Jeffers JL, Coelho-Litfie EM, Cheİnquer H et al: Procol-tagcn-III peptide and ehronic viral C hepatilis. Am J Gastroenterol.; 1995; 9: 1437.
20. Guechot J, Poupon RE, Ponpon R: Serum hyaluronan as a marker of liver fibrosis. J Hepatol.; 1995; 22:103.
21. Jeröme G, Loria A, Serfaty L et al: Serum hyaluronan as a marker of liver fibrosis in ehronic viral hepatitis C: ef-fcet of ?-iııterfcron therapy. J Hepatol. 1995; 22: 22.
22. Slickel F, Urbaschek R, Schuppan D, Pocschl G, Oester-ling C, Conradt C, Mccuskey RS, Simanowski UA and Settz HK: Serum collagen Type VI and XIV and hyalu-ronic acid as early sndicators for altcred conneclive tissue (urnover in alcoholic liver disease. Dig Dis Sci; 2001; 46: 2025.
23. Npjgaard C, Johansen JS, Christensen E, Skovgaaıd LT, Price PA, Becker U: Serum levels of YKL-40 and PIIINP as prognostic markers in patients wilh alcoholic liver disease. The EMALD group. J Hepatol; 2003; 39: 179.
24. Piletlc C, Rousselet MC, Bedossa P et al: Histopathoio-gical evaluation of liver fibrosis: quanlitative image aualysis vs semi-quaulilatîve scores. J Hepatol.; 1998; 28; 439,
25. Thabut D, Simoıı M, Myers RP, Messous D, Thiibault V, Imberl-Bismuth F, Poynard T: Noninvasive predicüon of fibrosis in palienfs wilh ehronic lıepatitis C. Hepatology; 2003;37:1220.
26. Korner T, Kropf J, Kosche B, Kristali! II, Jaspersen D, Gressner AM: Improvemenl of prognostic powcr of the Chİld-Pugh elassification of liver cirrhosis by hyaluronan. J Hepatol; 2003; 39: 947.
27. Min Zheng, Wei-Min Cai, Hong-Lei Weng, Rong-Hııa Liu: ROC curves in evaluation of serum fibrosis indices for hepatic fibrosis. World J Gastroenterol; 2002; 8:1073.
28. The French METAVİR Cooperativc Study Group. Inlıa-observer and interobserver variations in liver biopsy in-terpretation in patienls wilh ehronic hepatitis C. Hepalo-logy. 1994; 20:15.
29. Knodell RG, Ishak KG, Black WC et al: Formulation and application of numerical scoring systcın for accessing histologycal aetivity in asymtomalic ehronic aetive hepatitis. Hepatology. 198L; 1:431.
30. Nord HJ: Biopsy diagnosis of cirrhosis: blind percutaneous versııs guided direct vision lechniqucs - a review. GastrointestEndosc; 1982; 28: 102.

Thank you for copying data from http://www.arastirmax.com